Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)
Ailawadhi, Sikander, Parrondo, Ricardo D, Paulus, Aneel, Laplant, Betsy, Alegria, Victoria R., Zimmerman, Ashley, Chapin, Dustin, Sher, Taimur, Roy, Vivek, Chanan-Khan, Asher
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients
Ailawadhi, Sikander, Parrondo, Ricardo D, Perez, Gabriela, Kharfan-Dabaja, Mohamed A., Murthy, Hemant S., Ayala, Ernesto, O'Brien, Patrick J, Roy, Vivek, Alegria, Victoria R., Zimmerman, Ashley, Chapin, Dustin, Lanier, Stephanie, Kasik, Carly, Bradley, Schannon, Sher, Taimur, Paulus, Aneel, Chanan-Khan, Asher
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
Ailawadhi, Sikander, Parrondo, Ricardo D, Laplant, Betsy, Alegria, Victoria R., Elliott, Jamie B, Zimmerman, Ashley, Heslop, Keisha, Chapin, Dustin, Sher, Taimur, Roy, Vivek, Rasheed, Ahsan, Paulus, Aneel, Chanan-Khan, Asher
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
Parrondo, Ricardo D., Dutta, Navnita, LaPlant, Betsy R., Elliott, Jamie, Fernandez, Andre, Zimmerman, Ashley, Cicco, Gina, Han, Bing, Heslop, Keisha, Chapin, Dustin, Sher, Taimur, Roy, Vivek, Rasheed, Ahsan, Das, Saurav, Chanan‐Khan, Asher A., Paulus, Aneel, Ailawadhi, Sikander
Published in British journal of haematology (01.05.2024)
Published in British journal of haematology (01.05.2024)
Get full text
Journal Article